Escalon Medical Corp operates in the healthcare market specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology... Show more
Expect a price pull-back in the near future.
The 10-day moving average for ESMC crossed bearishly below the 50-day moving average on July 18, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 25 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESMC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ESMC entered a downward trend on July 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on July 16, 2025. You may want to consider a long position or call options on ESMC as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ESMC just turned positive on July 16, 2025. Looking at past instances where ESMC's MACD turned positive, the stock continued to rise in of 61 cases over the following month. The odds of a continued upward trend are .
ESMC moved above its 50-day moving average on July 16, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ESMC advanced for three days, in of 76 cases, the price rose further within the following month. The odds of a continued upward trend are .
ESMC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESMC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.705) is normal, around the industry mean (24.469). P/E Ratio (9.852) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.373) is also within normal values, averaging (42.883).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of medical devices and pharmaceuticals
Industry MedicalSpecialties
A.I.dvisor tells us that ESMC and MDRSF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESMC and MDRSF's prices will move in lockstep.
Ticker / NAME | Correlation To ESMC | 1D Price Change % | ||
---|---|---|---|---|
ESMC | 100% | -2.91% | ||
MDRSF - ESMC | 21% Poorly correlated | N/A | ||
MASI - ESMC | 9% Poorly correlated | -0.69% | ||
FONR - ESMC | 8% Poorly correlated | -1.06% | ||
MDT - ESMC | 8% Poorly correlated | -0.28% | ||
HBIO - ESMC | -1% Poorly correlated | +12.07% | ||
More |